Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Abu-Elmagd KM et al. | Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1721271 |
Abu-Elmagd KM et al. | Strategy of FK 506 therapy in liver transplant patients: effect of graft function. | 1991 | Transplant. Proc. | pmid:1721272 |
Ericzon BG et al. | Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721273 |
Jain AB et al. | Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. | 1991 | Transplant. Proc. | pmid:1721274 |
Connelly PR | Thermodynamics of interaction of FK 506-binding protein and its ligands. | 1991 | Transplant. Proc. | pmid:1721304 |
Donnelly JG and Soldin SJ | Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721305 |
Rosborough SL et al. | Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. | 1991 | Transplant. Proc. | pmid:1721306 |
Zeevi A et al. | In vitro assessment of FK 506 immunosuppressive activity in transplant patients. | 1991 | Transplant. Proc. | pmid:1721307 |
D'Alessandro AM et al. | FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1721335 |
Lewis WD et al. | FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. | 1991 | Transplant. Proc. | pmid:1721336 |
Woodle ES et al. | FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. | 1991 | Transplant. Proc. | pmid:1721337 |
Shaw BW et al. | FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. | 1991 | Transplant. Proc. | pmid:1721338 |
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721367 | |
Starzl TE et al. | Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. | 1991 | Transplant. Proc. | pmid:1703351 |
Darras FS et al. | Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721368 |
Shapiro R et al. | Kidney transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703352 |
Todo S et al. | Clinical small bowel or small bowel plus liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721369 |
Tzakis AG et al. | Use of FK 506 in pediatric patients. | 1991 | Transplant. Proc. | pmid:1703353 |
Fries D et al. | Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. | 1991 | Transplant. Proc. | pmid:1721370 |
Jain AB et al. | Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1703354 |
DiMartini A et al. | Psychiatric morbidity in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721399 |
Lopez OL et al. | Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721400 |
Viebahn R et al. | Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721401 |
Heitman J et al. | FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1705713 |
Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
Langrehr JM et al. | FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. | 1991 | Transplant. Proc. | pmid:1721430 |
Gotoh M et al. | Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1721431 |
Valdivia LA et al. | Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721432 |
Wu GD et al. | FK 506 inhibits the development of transplant arteriosclerosis. | 1991 | Transplant. Proc. | pmid:1721433 |
Fung JJ et al. | Current status of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1712133 |
Francavilla A et al. | Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. | 1991 | Hepatology | pmid:1712337 |
Aoki H | [FK 506, a new immunosuppressant produced by a Streptomyces]. | 1991 | Nippon Rinsho | pmid:1712403 |
Hultsch T et al. | Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1712484 |
McManus BM et al. | Impact of FK 506 on myocarditis in the enteroviral murine model. | 1991 | Transplant. Proc. | pmid:1721463 |
Nossal GJ | Summary of the First International FK 506 Congress: perspectives and prospects. | 1991 | Transplant. Proc. | pmid:1721464 |
Staruch MJ et al. | Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. | 1991 | Int. J. Immunopharmacol. | pmid:1721613 |
Matsuura T et al. | [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. | 1991 | Hinyokika Kiyo | pmid:1721767 |
Henderson DJ et al. | Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. | 1991 | Immunology | pmid:1715317 |
DeFranco AL | Signal transduction. Immunosuppressants at work. | 1991 | Nature | pmid:1715515 |
Flanagan WM et al. | Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. | 1991 | Nature | pmid:1715516 |
McWhinnie DL and Morris PJ | Combination drug therapies for immunosuppression in transplantation. | 1991 | Ann. Acad. Med. Singap. | pmid:1724724 |
Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
Starzl TE et al. | Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. | 1991 | Transplantation | pmid:1718068 |
Morris RE et al. | Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. | 1991 | Transplant. Proc. | pmid:1703698 |
Lane WS et al. | Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. | 1991 | J. Protein Chem. | pmid:1718307 |
Goto S et al. | Effect of FK 506 and cyclosporine on heart allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1703700 |
James DG | Which immunomodulator? | 1991 | Br J Clin Pract | pmid:1718384 |
Flavin T et al. | Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. | 1991 | Transplant. Proc. | pmid:1703701 |
Jiang H et al. | Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703702 |